CytoDyn (OTCQB:CYDY +10.1%) has completed the rolling submission
of its U.S. marketing application seeking approval to use leronlimab,
combined with highly active antiretroviral therapy (HAART), in
treatment-experienced HIV patients, a Fast Track-tagged indication.
The company is also testing the viral entry
inhibitor in COVID-19. A Phase 2 study in mild-to-moderately ill
patients and a Phase 2b/3 trial in severely and critically ill patients
are in process in the U.S.
The company says leronlimab inhibits (binds to) a
protein on the surface of certain immune cells called Cysteine-Cysteine
Chemokine Receptor 5 (CCR5) which plays a key role in modulating immune
cell trafficking in sites of inflammation, so it may have potential to
treat COVID-19.
https://seekingalpha.com/news/3564673-cytodyn-up-10-on-completion-of-leronlimab-application-for-hiv
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.